Cargando…

Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?

Background Various predictive models have been developed which incorporates patient risk factors into the selection of optimal antiemetic therapy, one of which is chemotherapy-induced nausea and vomiting (CINV) risk scoring system developed by Multinational Association of Supportive Care in Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Souza, Anita, Pawar, Dipalee, Ramaswamy, Anant, Turkar, Siddharth, Bhargava, Prabhat, Kapoor, Akhil, Mandavkar, Sarika, Nashikkar, Chaitali, Ostwal, Vikas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Private Ltd 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197652/ https://www.ncbi.nlm.nih.gov/pubmed/34131576 http://dx.doi.org/10.1055/s-0041-1726136

Ejemplares similares

Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses
por: Clark-Snow, Rebecca, et al.
Publicado: (2017)

Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022)

The Clinical Observation of Acupuncture Combined With Antiemetic Drugs in the Prevention and Treatment of CINV in Breast Cancer Patients
por: Kong, Fanming, et al.
Publicado: (2022)

Erratum: The clinical observation of acupuncture combined with antiemetic drugs in the prevention and treatment of CINV in breast cancer patients
Publicado: (2022)

Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study
por: Kimura, Hiroaki, et al.
Publicado: (2015)

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
por: Rashad, Noha, et al.
Publicado: (2017)

Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine
por: Yeo, Winnie, et al.
Publicado: (2020)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
por: May, Megan Brafford, et al.
Publicado: (2016)

The Antiemetic Mechanisms of Gingerols against Chemotherapy-Induced Nausea and Vomiting
por: Dai, Yongzhao, et al.
Publicado: (2022)

Antiemetics and Cancer Chemotherapy
por: Wilkinson, P.W.
Publicado: (1983)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
por: Zhang, L, et al.
Publicado: (2018)

A Study on Utilization and Evaluation of Antiemetics in Chemotherapy-induced Nausea and Vomiting
por: Baburaj, Gayathri, et al.
Publicado: (2017)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
por: Chang, Jianhua, et al.
Publicado: (2020)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma
por: Giagnuolo, Giovanna, et al.
Publicado: (2019)

Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey
por: Aapro, Matti, et al.
Publicado: (2018)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting
por: Alamri, Abdulrahman, et al.
Publicado: (2018)

Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Schwartzberg, Lee, et al.
Publicado: (2013)

Guidelines versus individualized care for the management of CINV
por: Clemons, Mark
Publicado: (2018)

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
por: Choi, Brian S., et al.
Publicado: (2014)

Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis
por: Xie, Jiyi, et al.
Publicado: (2022)

Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?
por: Kapoor, Akhil, et al.
Publicado: (2020)

Antiemetic activity of volatile oil from Mentha spicata and Mentha × piperita in chemotherapy-induced nausea and vomiting
por: Tayarani-Najaran, Z, et al.
Publicado: (2013)

Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis
por: Qiu, Tingting, et al.
Publicado: (2020)

CINV: still troubling patients after all these years
por: Aapro, Matti
Publicado: (2018)

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
por: Ramaswamy, Anant, et al.
Publicado: (2018)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

Research Progress on the Antiemetic Effect of Traditional Chinese Medicine Against Chemotherapy-Induced Nausea and Vomiting: A Review
por: Zhao, Yao-Zhong, et al.
Publicado: (2022)

Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects
por: Shimamoto, Fukutaro, et al.
Publicado: (2021)

Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis
por: Schwartzberg, Lee, et al.
Publicado: (2023)

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients
por: Kaushal, Pulkit, et al.
Publicado: (2015)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV
por: Jin, Yilan, et al.
Publicado: (2021)

The emerging role of olanzapine in paediatric CINV control: A review
por: Barušić, Anabella Karla
Publicado: (2022)

Combination of Antiemetics for the Prevention of Postoperative Nausea and Vomiting in High-Risk Patients
por: Kim, Eun Jin, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_9j6og36dm0ll95mm96afsc5mjl